GCP
ADAP

GSA Capital Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

GSA Capital Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-99,662
Closed -$95K – 1563
2024
Q3 		$95K Buy
+99,662
New +$113K 0.01% 1495
2024
Q2 		– Sell
-370,179
Closed -$585K – 1583
2024
Q1 		$585K Sell
370,179
-138,629
-27% -$167K 0.05% 790
2023
Q4 		$403K Buy
+508,808
New +$287K 0.03% 936
2023
Q3 		– Sell
-34,307
Closed -$32K – 1446
2023
Q2 		$32K Sell
34,307
-14,330
-29% -$17.1K ﹤0.01% 1432
2023
Q1 		$53K Sell
48,637
-92,447
-66% -$143K 0.01% 1398
2022
Q4 		$206K Sell
141,084
-239,959
-63% -$389K 0.03% 1168
2022
Q3 		$410K Buy
+381,043
New +$700K 0.05% 722
2022
Q2 		– Sell
-69,612
Closed -$143K – 1347
2022
Q1 		$143K Sell
69,612
-14,517
-17% -$39.2K 0.02% 1238
2021
Q4 		$315K Sell
84,129
-400,653
-83% -$1.82M 0.04% 894
2021
Q3 		$2.51M Sell
484,782
-28,606
-6% -$128K 0.26% 30
2021
Q2 		$2.19M Buy
513,388
+420,276
+451% +$2.04M 0.25% 47
2021
Q1 		$494K Sell
93,112
-229,632
-71% -$1.31M 0.08% 359
2020
Q4 		$1.74M Buy
322,744
+248,797
+336% +$1.35M 0.28% 36
2020
Q3 		$590K Buy
+73,947
New +$647K 0.1% 303
2020
Q2 		– Sell
-19,219
Closed -$52K – 582
2020
Q1 		$52K Sell
19,219
-83,675
-81% -$278K 0.01% 958
2019
Q4 		$123K Buy
102,894
+33,189
+48% +$35.4K 0.01% 1322
2019
Q3 		$105K Buy
69,705
+12,060
+21% +$28.2K 0.01% 1274
2019
Q2 		$232K Sell
57,645
-11,464
-17% -$46.7K 0.03% 1165
2019
Q1 		$297K Buy
+69,109
New +$322K 0.03% 1000
2018
Q2 		– Sell
-75,912
Closed -$852K – 1635
2018
Q1 		$852K Buy
+75,912
New +$664K 0.05% 765
2017
Q3 		– Sell
-53,866
Closed -$242K – 1566
2017
Q2 		$242K Buy
+53,866
New +$282K 0.02% 1418
2016
Q4 		– Sell
-11,803
Closed -$83K – 1719
2016
Q3 		$83K Buy
+11,803
New +$90K ﹤0.01% 1710

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's ADAP Position: Q4 2024 in Review

GSA Capital Partners sold out of Adaptimmune Therapeutics (ADAP) in Q4 2024, closing a stake of 99,662 shares — an estimated $95K sold.

GSA Capital Partners first reported a position in ADAP in Q3 2016 and held it in 22 quarters. The position peaked at $2.51M in Q3 2021. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

  • GSA Capital Partners reported no remaining Adaptimmune Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GSA Capital Partners sold 99,662 Adaptimmune Therapeutics shares in Q4 2024, an estimated $95K.
  • GSA Capital Partners first reported a position in Adaptimmune Therapeutics in Q3 2016 and held it in 22 quarters.
  • GSA Capital Partners's Adaptimmune Therapeutics position peaked at $2.51M in Q3 2021.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.